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Available online xxxxBackground:Mitochondrial functions are exploited in cancer and provide a validated therapeutic target. How-
ever, how this process is regulated has remainedmostly elusive and the identification of new pathways that con-
trol mitochondrial integrity in cancer is an urgent priority.
Methods:We studied clinically-annotated patient series of primary and metastatic prostate cancer, representa-
tive cases of multiple myeloma (MM) and publicly available genetic databases. Gene regulation studies involved
chromatin immunoprecipitation, PCR amplification and Western blotting of conditional Myc-expressing cell
lines. Transient or stable gene silencing was used to quantify mitochondrial functions in bioenergetics, outer
membrane permeability, Ca2+ homeostasis, redox balance and cell death. Tumorigenicity was assessed by cell
proliferation, colony formation and xenograft tumour growth.
Findings: We identified Mitochondrial Fission Factor (MFF) as a novel transcriptional target of oncogenic Myc
overexpressed in primary and metastatic cancer, compared to normal tissues. Biochemically, MFF isoforms,
MFF1 and MFF2 associate with the Voltage-Dependent Anion Channel-1 (VDAC1) at the mitochondrial outer
membrane, in vivo. Disruption of this complex by MFF silencing induces general collapse of mitochondrial func-
tions with increased outer membrane permeability, loss of inner membrane potential, Ca2+ unbalance, bioener-
getics defects and activation of cell death pathways. In turn, this inhibits tumour cell proliferation, suppresses
colony formation and reduces xenograft tumour growth in mice.
Interpretation:AnMFF-VDAC1 complex is a novel regulator of mitochondrial integrity and actionable therapeutic
target in cancer.
© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cancer therapy1. Introduction
As tumours tend to shift their metabolism towards glycolysis, even
when oxygen is present [1], the importance of mitochondria in cancer
has long remained uncertain [2]. This perception has now changed [3]er of Health; National Research
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driver of primary and metastatic disease [4] and validated therapeutic
target [5]. The molecular requirements of this process are beginning to
emerge, but mitochondrial-directed cancer therapies are still in infancy
[6], there is a paucity of druggable mitochondrial targets [7], and even
established drugs designed to (re)activate mitochondrial cell death
[8], including Bcl2 antagonists [8] or Smac mimetics [9] have limited
disease indications and often short-lived efficacy due to resistance
mechanisms [10].
In this context, mitochondria are hubs of multiple cell death path-
ways [11]. How these processes are reprogrammed in cancer to pro-
mote aberrant cell survival is far from understood [12]. However, a
sudden increase in the permeability of the mitochondrial outer-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Research in context
Evidence before this study
Mitochondria are hubs of multiple signalling pathways that be-
come invariably subverted in cancer to sustain energy production,
aberrant cell survival and buffering of oxidative stress. Despite ex-
tensive efforts, the regulators of mitochondrial integrity in cancer
have not been clearly identified, and this has hampered the devel-
opment of new therapies.
Added value of this study
We identified a novel crosstalk between mitochondrial pathways
exploited in cancer, including mitochondrial dynamics and the
control of mitochondrial cell death. This involves a newmolecular
association between Mitochondrial Fission Factor (MFF) and the
Voltage-Dependent Anion Channel-1 (VDAC1) at the organelle
outer membrane, which is required tomaintain cancer bioenerget-
ics, prevent cell death and support tumour growth.
Implications of all the available evidence
Disruption of protein-protein interactions at the mitochondrial
outer membrane is feasible and has generated successful cell-
death modifying drugs currently in clinical practice. Such thera-
peutic targeting of an MFF-VDAC1 complex may provide a novel
strategy to shut off multiple mitochondrial functions exploited
for tumour progression.
2 J.H. Seo et al. / EBioMedicine xxx (2019) xxxmembrane [13], mainly driven by pro-apoptotic Bcl2 family proteins
[14], is a requirement of some cell death mechanisms culminating
with the release of apoptogenic proteins in the cytosol [11]. Isoforms
of Voltage-Dependent Anion Channel (VDAC) are key effectors of this
process [15], maintaining ion and metabolite exchange [16] and overall
mitochondrial homeostasis, including in cancer [17]. The mechanisms
that connect increased mitochondrial outer membrane permeability to
downstream events of inner membrane permeability transition, with
loss of transmembrane potential, uncoupling of the TCA cycle and acti-
vation of regulated necrosis remain to be delineated [12], and the iden-
tity of key regulators in these responses has remained elusive [18].
Another mitochondrial pathway that is commonly exploited in can-
cer is mitochondrial dynamics [19], an adaptive process that continu-
ously adjusts the size, shape and subcellular position of mitochondria
to changes in cellular environment(s) [20]. In particular, mitochondrial
fragmentation, or fission initiates with the binding of Dynamin-Related
Protein-1 (Drp1) [21] tooneof its receptors,Mitochondrial FissionFactor
(MFF) on themitochondrial outer membrane [22,23]. This process has
been implicated in tumour progression [24], and there is evidence that
mitochondrial fission couples to the machinery of organelle cell death,
including apoptosis [25], mitochondrial integrity [26] and proapoptotic
Bcl2 proteins [27], but a direct,mechanistic link between effectors ofmi-
tochondrialfission andmitochondrial cell death has not been identified.
In this study, we uncovered a novelmolecular interface betweenmi-
tochondrial dynamics and the control ofmitochondrial integrity as a po-
tential therapeutic target in disparate tumours.2. Materials and methods
2.1. Patient samples
A clinically-annotated series of 192 patients with histologically con-
firmed diagnosis of primary prostate cancer [28] together with 17Please cite this article as: J.H. Seo, E. Agarwal, Y.C. Chae, et al., Mitochondr
permeability in can..., EBioMedicine, https://doi.org/10.1016/j.ebiom.2019prostate cancer metastases to different organs were used in this study
(Supplementary Table S1). Archival tissues and clinical recordswere ob-
tained from Fondazione IRCCS Ca’ Granda Hospital in Milan (Italy)
under a protocol approved by the Institutional Review Boards (IRB) of
Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico (code
1381/11). Because of the retrospective nature of this study and the
use of data anonymization practices, the need for written informed con-
sent was waived. For patients with primary prostate cancer, epithelial
tissue samples for normal prostate, prostatic intraepithelial neoplasia
(PIN) and prostatic adenocarcinoma (AdCa)were arranged in tissuemi-
croarrays (TMA) blocks for immunohistochemical evaluations. Distant
metastases were analysed as full sections. Representative bone
marrow-derived samples of monoclonal gammopathy of uncertain sig-
nificance (MGUS, n=7) ormultiplemyeloma (n=8)were also exam-
ined by immunohistochemistry. Patient samples for this study were
collected between the years 2004–2006 (primary prostate cancer),
2012–2012 (metastatic prostate cancer) and 2009–2018 (multiple my-
eloma and MGUS).
2.2. Plasmids and gene silencing
cDNA clones encoding human MFF1, MFF5 or control vector were
purchased from GeneCopoeia (Cat. n. EX-Z4766, EX-Z0675). An MFF2
cDNA was obtained from Addgene. Transfection of plasmid DNA (1
μg) was carried out using 2 μl X-Treme gene HP (Roche) for 24 h. For
gene knockdown experiments, tumour cells were transfected with con-
trol, non-targeting small interfering RNA (siRNA) pool (D-001810,
Dharmacon) or specific siRNA pools targeting MFF (Santa Cruz#sc-
94736) or individual MFF-directed siRNA sequences (Santa Cruz #Sc-
94,36-A and C). An additional siRNA sequence targetingMFF (SantaCruz
#SC-94736-A: 5′-GAACAAAGAACGUGCUAAAUUUU-3′) was synthe-
sized by Dharmacon. Cells were transfected with the various siRNA
(30–60nM) in the presence of Lipofectamine RNAiMAX (Invitrogen)
at a 1:1 ratio (vol siRNA 20μM:vol Lipofectamine RNAiMAX) and proc-
essed as described [29]. Two independent shRNA sequences were
also used for targeting human MFF: TRCN0000167581 and
TRCN0000343573 (Sigma Aldrich). An empty pLKO-based lentivirus
was used as control. Individual clones of PC3 and DU145 cells stably ex-
pressing MFF-directed shRNA sequences were generated by infection
with lentiviral particles, followed by a 2-week selection in the presence
of puromycin at 2μg/ml.
2.3. Cells and cell culture
Human prostate adenocarcinoma (LNCaP, C4-2, C4-2B, PC3 and
DU145), normal prostatic epithelial (RWPE-1) and human glioblastoma
(LN229) cells were obtained from the American Type Culture Collection
(ATCC, Manassas, VA), and maintained in culture according to the
supplier's specifications. Benign prostatic hyperplasia (BPH-1) cells
were a gift from Dr. Simon Hayward (Vanderbilt University, Nashville,
TN) and primary human foreskin fibroblasts (HFF) were a gift from Dr.
Meenhard Herlyn (The Wistar Institute, Philadelphia, PA). Neuroblas-
toma SHEP21N, SHEP21-NMycER cells containing a conditionally-
regulated N-Myc transgene were as described [30] and used in recent
studies of mitochondrial reprogramming in cancer [29]. In these cells,
treatment with 50 ng/ml doxycycline (Dox) for 48 h suppresses N-
Myc expression, whereas addition of 4-hydroxytamoxifen (4OHT, 0.5
μg/ml) results in strong N-Myc induction. Cell passaging was limited
to b40 passages from receipt and cell lines were authenticated by STR
profiling with AmpFlSTR Identifiler PCR Amplification Kit (Life Technol-
ogies) at theWistar Institute's Genomics Shared Resource. Mycoplasma
free-cultures were confirmed at the beginning of the studies, and every
2 months afterwards, by direct PCR amplification using Bioo Scientific
Mycoplasma Primer Sets (cat. #375501) and Hot Start polymerase
(QIAGEN).ial fission factor is a novel Myc-dependent regulator of mitochondrial
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PC3 cells transfected with siCtrl or Myc-directed siRNA (siMyc) for
72 h were used for ChIP experiments, as described [29] and incubated
with non-binding rabbit IgG or a rabbit monoclonal antibody to Myc
(Abcam #Ab32072). Real-time PCR amplification of chromatin frag-
ments was carried out using SYBR green master mix (Applied
Biosystems) on an ABI7500 sequence detection system.
2.5. Immunofluorescence and confocal microscopy
PC3 or DU145 cells transfected with siCtrl or MFF-directed siRNA
(siMFF), or alternatively, expressing control plasmid or MFF cDNA
were fixed in formalin/PBS (4% final concentration) and processed for
immunofluorescence with primary antibodies against MFF (1:100) or
MTCO2 (mitochondrial cytochrome c oxidase subunit II, 1:500) as de-
scribed [29]. Secondary antibodies conjugated to Alexa488, TRITC or
Alexa633 were used. F-actin was stained with phalloidin Alexa (1:200
dilution). After washes, slides were analysed by Z-stack imaging and
confocal microscopy (SPF5 II, Leica). At least 70 cells per sample were
analysed and mitochondrial morphologies were classified as
fragmented (individual round- or rod-shaped organelles, N80%
displaying an axial length of b4 μm), intermediate (majority b4 μm),
or tubular (often interconnected in branched networks, N80% displaying
a length of N4 μm).
2.6. Immunoprecipitation (IP)
Cell extracts prepared in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
1mMEDTA containing 1% CHAPS, EDTA-free Protease Inhibitor Cocktail
(Sigma-Aldrich) and Phosphatase Inhibitor Cocktail PhosSTOP (Roche)
were immunoprecipitated with anti-Flag-conjugated beads (Sigma-Al-
drich) and processed as described [31].
2.7. Mitochondrial outer membrane permeability
PC3 cells (3×105) transfectedwith siCtrl or siMFFwere stainedwith
calcein (0.01 μM) and cobalt chloride (0.4 μM) (MitoProbe Transition
Pore Assay, Molecular Probes, cat# M34153) for 15 min in HBSS (with
calcium and without phenol red), washed in PBS, pH 7.4, and analysed
on a FACS Celesta flow cytometer at 488 nm excitation and emission fil-
ters. Intact cells were gated in the FSC/SSC plot to exclude small debris.
2.8. Mitochondrial membrane potential
Normal prostatic epithelial RWPE1 or BPH-1 cells or prostate cancer
PC3 or DU145 cells were transfected with siCtrl or siMFF and analysed
on a FACS Calibur flow cytometer, with the TMRE signal as FL1. Intact
cells were gated in the FSC/SSC plot to exclude small debris. The
resulting FL1 data were plotted on a histogram.
2.9. Cellular respiration and mitochondrial ROS
PC3 or DU145 cells were transfected with siCtrl or siMFF and
analysed after 48 h for Oxygen Consumption Rates (OCR) or Extracellu-
lar Acidification Rates (ECAR) using an Extracellular Flux System 24 In-
strument (Seahorse Bioscience, Billerica, MD) using 2.5 × 104 cells
plated in each well of a Seahorse XF24 cell culture plate (100 μl). After
4 h 150 μl of media was added to each well, and the cells were grown
for 24 h at 37 °C in 5% CO2. The media was then exchanged with unbuf-
fered DMEM XF assay media (Seahorse Bioscience) supplemented with
2 mM glutaMAX, 1 mM sodium pyruvate and 5 mM glucose (pH 7.4 at
37 °C) for 30 min at 37 °C and ~0.04% CO2 before the experiment. OCR
was monitored in basal condition (before any addition) and after se-
quential addition of oligomycin (1.25 μM), FCCP (0.4 μM), and
antimycin plus rotenone (0.25 μM), all dissolved in DMSO. OCR wasPlease cite this article as: J.H. Seo, E. Agarwal, Y.C. Chae, et al., Mitochondr
permeability in can..., EBioMedicine, https://doi.org/10.1016/j.ebiom.2019quantified after three cycles of mixing (150 s), waiting (120 s), and
measuring (210 s). This cycle was repeated following each injection.
In some experiments, PC3 cells transfected with siCtrl or siMFF were in-
cubated with 5 μMMitoSOX Red (Life Technology) for 10 min in com-
plete medium, washed three times in warm PBS and counted. Ten
thousand stained cells in 100 μl of PBS were analysed on a microplate
florescent reader (Ex/Em = 510/580 nm, Molecular Devices).
Unlabelled cells were used as basal control.2.10. Calcium measurements
PC3 cells (3× 105) transfectedwith siCtrl or siMFFwere stainedwith
calcium-sensitive dyes to determine changes in calcium concentrations
in cytosol, mitochondria and endoplasmic reticulum (ER). Calcium
levels in cytosol and ER were measured by staining the cells with
FLUO3-AM (1 μM) and FLUO-5 N (5 μM), respectively for 1 h, washed
in PBS, pH7.4, and analysed on LSR18flow cytometer at 506/526nmex-
citation and emission filters, respectively. Rhod2-AM (10 μM)was used
to measure calcium levels in mitochondria. For these experiments, cells
were stained for 1 h and analysed by flow cytometry at 552/581 nm ex-
citation and emission filters respectively. Intact cells were gated in the
FSC/SSC plot to exclude small debris.2.11. Mitophagy assay
Mitophagy was examined using a FACS-based analysis of mitochon-
drial targeted mKeima-Red fluorescence reporter (Addgene, cat.
#56018). PC3 cells stably expressing mKeima were transfected with
siCtrl or siMFF for 72 h. Cells were detached by trypsin treatment,
washed and suspended in PBS followed by analysis on an LSR 18 flow
cytometer at 405 and 561 nm lasers and 610/20 filters. Intact cells
were gated in the FSC/SSC plot to exclude small debris.2.12. Cell death
PC3 or DU145 cells (1 × 106) were transfected with siCtrl or siMFF,
labelled for Annexin V and propidium iodide (PI) (BD Biosciences)
and analysed by multiparametric flow cytometry. Alternatively,
mitochondria-associated changes in cell viability were quantified by
an MTT assay or Trypan blue dye exclusion assay and light microscopy.
In some experiments, PC3 cells transfected with siCtrl or siMFF were
analysed for proteolytic processing of PARPwith or without stress stim-
uli, H2O2, nutrient deprivation or chemotherapeutic drugs, doxorubicin
or etoposide, by Western blotting.2.13. Colony formation assay
Four hundred PC3 or DU145 cells stably expressing pLKO or two in-
dependent MFF-targeting shRNA were plated in triplicate in 6-
multiwell plates and quantified macroscopically for colony formation
as described [31].2.14. Animal studies
Studies involving vertebrate animals (rodents) were carried out in
accordance with the Guide for the Care and Use of Laboratory Animals
(National Academies Press, 2011). Protocolswere approved by the Insti-
tutional Animal Care and Use Committee (IACUC) of The Wistar Insti-
tute (protocol #112625 and 112610). Groups of 4–6 weeks-old male
athymic nude mice (Crl:NU(NCr)-Foxn1nu, Charles River Laboratory)
were injected s.c. with PC3 clones (5 × 106 cells) stably transduced
with pLKO or MFF-directed shRNA and tumour volume was quantified
with a calliper over a two-week interval.ial fission factor is a novel Myc-dependent regulator of mitochondrial
.09.017
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Four μm-thick sections from each tissue block were stained with an
antibody to MFF (Protein Tech#17090-1-AP) using diaminobenzidine
(DAB) as a chromogen. Immunohistochemistry was performed using
Benchmark Ultra Roche Ventana immunostainer (Roche Group, Tucson,
AZ). All slides were counterstained with haematoxylin. Two patholo-
gists (V.V. and S.F.) blinded to clinical data evaluated and scored all
slides. When discrepancies occurred, the case was further reviewed to
reach an agreement score.
2.16. Statistical analysis
Data were analysed using the two-sided unpaired t, chi-square or
Kruskal-Wallis (with p value correction for multiple testing) tests
using a GraphPad software package (Prism 8.1) for Windows. Data are
expressed asmean± SD of replicates from a representative experiment
out of at least two or three independent determinations or as mean ±
SD of three individual experiments. A p value of b0.05 was considered
as statistically significant.
3. Results
3.1. Differential MFF overexpression in cancer
We began this study by examining the expression of mitochondrial
fission effectors, Drp1 [24] and its outer mitochondrial membrane re-
ceptor, MFF [22] in prostate cancer. Analysis of public databases showed
that MFF and Drp1 were amplified in castration-resistant and neuroen-
docrine prostate cancer (Fig. 1a), correlating with prostate cancerFig. 1.MFF overexpression in cancer. (a) Amplification of MFF and Drp1 in prostate cancer (77
prostate cancer. (b) TCGA correlation (n=380) betweenMFF expression and prostate cancer p
380) of MFF expression (log MFF copy number) and prostate cancer survival. A, alive at 5 years
expression by immunohistochemistry in a patient cohort of localized andmetastatic prostate ca
Insets, image magnification of selected regions. Right, MFF expression in prostate cancer meta
immunohistochemistry (IHC) in primary (e) or metastatic (f) prostate cancer. *, p= .01; **, p
Vis, visceral; LN, lymph nodes. (g and h) MFF expression in representative patient samples of
(MM, n= 8) by immunohistochemistry (g) and quantification of IHC score (h). Scale bar, 50 μ
Please cite this article as: J.H. Seo, E. Agarwal, Y.C. Chae, et al., Mitochondr
permeability in can..., EBioMedicine, https://doi.org/10.1016/j.ebiom.2019relapse (Fig. 1b) and abbreviated patient survival (Fig. 1c). In a cohort
of 192 patients with localized and metastatic prostate cancer (Supple-
mentary Table S1), we found that MFF levels increased from normal
prostate to prostatic intraepithelial neoplasia (PIN) and were the
highest in localized (Fig. 1d and e) and metastatic prostate cancer to
lymph nodes, bones and visceral sites (Fig. 1d and f), by immunohisto-
chemistry. These metastatic sites stained positive for prostate-specific
antigen (PSA), confirming their prostatic origin (Supplementary
Fig. S1a and b). In this patient series, increased MFF expression corre-
latedwith highGleason grade (Supplementary Fig. S1c), but not tumour
size (Supplementary Fig. S1d).
As an independent approach, we next looked at a genetic model of
prostate cancer, i.e. Transgenic Adenocarcinoma of the Mouse Prostate
(TRAMP). Prostatic tumours formed in TRAMPmice, including neuroen-
docrine (NE) prostate cancer, well-differentiated adenocarcinoma
(AdCa) and phyllodes-type tumours all expressed high levels of MFF,
by immunohistochemistry (Supplementary Fig. S2a). In contrast, Drp1
waspresent at low levels in tumours fromTRAMPmice (Supplementary
Fig. S2a). Consistent with these observations, most prostate cancer cell
lines expressed MFF, with the highest levels observed in castration-
resistant as opposed to androgen receptor (AR)-positive cell types (Sup-
plementary Fig. S2b). Other regulators of mitochondrial fusion (MFN1,
MFN2, Opa1) or fission (Drp1) showed more variable expression in
prostate cancer cell lines (Supplementary Fig. S2b).
Next, we asked if MFFwas overexpressed in other tumour types.We
found that MFF was highly expressed in patients with non-small cell
lung cancer (NSCLC) including cases of adenocarcinoma (AdCa) and
squamous cell carcinoma (SCC), compared to normal bronchus, by im-
munohistochemistry (our unpublished observations). In addition, MFF
was strongly expressed in cases of multiple myeloma (MM), comparedpatients, 107 samples). CRPC, castration-resistant prostate cancer; NEPC, neuroendocrine
rogression. NR, no recurrence at 5 years; R, recurrence at 5 years. (c) TCGA correlation (n=
; ND, alive with no evidence of disease at 5 years; D, dead with disease at 5 years. (d) MFF
ncer (n=192). N, normal; PIN, prostatic intraepithelial neoplasia; AdCa, adenocarcinoma.
stases to bone or lungs. Scale bar, 100 μm. (e and f) Quantification of MFF expression by
= .003; ***, p b .0001 (by two-sided unpaired t-test; all compared to normal prostate).
Monoclonal Gammopathy of Uncertain Significance (MGUS, n= 7) or Multiple Myeloma
m. ***, p b .0001 (by two-sided unpaired t-test).
ial fission factor is a novel Myc-dependent regulator of mitochondrial
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(MGUS), by immunohistochemistry (Fig. 1g and h).
3.2. MFF is a novel Myc transcriptional target
To begin elucidating howMFF becomes overexpressed in cancer, we
next focused on theMyc oncogene,which is a key disease driver in pros-
tate cancer and MM. Analysis of ChIP-Seq tracks demonstrated time-
dependent accumulation of Myc at the MFF promoter in Burkitt lym-
phoma P493 cells as well as neuroblastoma BE2C, Kelly and NGP cell
lines (Fig. 2a). In chromatin immunoprecipitation (ChIP) experiments,
Myc readily bound to the promoter of MFF in PC3 cells, in a reaction
abolished by siRNA knockdown of Myc (Fig. 2b). Consistent with these
data, Myc silencing by siRNA, but not control siRNA, reduced MFF
mRNA levels (Fig. 2c) and protein expression (Fig. 2d) in PC3 cells, by
quantitative PCR and Western blotting, respectively.
To independently validate these results, we next used the model of
Shep21 neuroblastoma cells engineered with doxycycline (Dox)-regu-
lated conditional ablation of Myc, or, alternatively, 4-hydroxy-
tamoxifen (4OHT)-dependent Myc induction (Shep21-ER). Addition of
Dox abolished Myc mRNA levels in Shep21 cells (Fig. 2e), and this was
associated with reduced MFF mRNA (Fig. 2f) and protein (Fig. 2g) ex-
pression, compared to control transfectants. Reciprocally, addition of
4OHT to Shep21-ER cells increased the mRNA levels of Myc (Fig. 2h)
as well as MFF (Fig. 2i), compared to cultures in the absence of 4OHT.
3.3. MFF controls mitochondrial fission in cancer
Based on these data, we next examined the function of MFF in can-
cer. Processing of the human MFF locus is predicted to generate atFig. 2.MFF is a novel transcriptional target of oncogenic Myc. (a) ChIP-Seq tracks of time-depen
points (t= 0, 1 and 24 h) after removal of doxycycline (Dox) or neuroblastoma BE2C, Kelly or
with control non-targeting siRNA (siCtrl) or Myc-directed siRNA (siMyc). IgG, non-binding IgG
cells were transfected with siCtrl or siMyc and analysed for MFF expression by quantitative P
(e) Neuroblastoma Shep21 cells stably transfected with a Dox-regulated conditional Myc-d
absence of Dox, by quantitative PCR. Mean ± SD. (f and g) The conditions are as in (e) and S
(f) or Western blotting (g). Mean ± SD. ***p b .0001 (by two-sided unpaired t-test). (h and i)
were analysed for changes in Myc (h) or MFF (i) mRNA expression with or without 4OHT by q
Please cite this article as: J.H. Seo, E. Agarwal, Y.C. Chae, et al., Mitochondr
permeability in can..., EBioMedicine, https://doi.org/10.1016/j.ebiom.2019least five protein isoforms by alternative splicing (Supplementary
Fig. S3a). Of these,MFF1 andMFF2were themost abundantly expressed
isoforms in PC3 cells (Supplementary Fig. S3b). In addition, transfection
of Flag-MFF1 in these settings produced levels of recombinant protein
comparable to endogenous MFF1 (Supplementary Fig. S3b). Using this
approach, expression of MFF1 in PC3 cells resulted in extensive mito-
chondrial fragmentation, i.e. fission, and loss of mitochondrial elonga-
tion (Supplementary Fig. S3c and d), consistent with a role of this
pathway in mitochondrial dynamics [22].
To carry out reciprocal experiments, we next established two inde-
pendent siRNA sequences that reduce the expression of allMFF isoforms
in PC3 cells (Supplementary Fig. S4a). In parallel, we also generated
clones of DU145 and PC3 cells stably transduced with pLKO or MFF-
directed shRNA, resulting in loss of endogenous MFF levels, compared
to pLKO-transduced cultures (Supplementary Fig. S4b). MFF knock-
down in these settings did not significantly affectmitochondrial dynam-
ics, as comparable fractions of elongated or fragmented mitochondria
were observed in control transfectants and MFF-silenced cells (Supple-
mentary Fig. S4c and d). Consistent with these data, MFF silencing did
not affect mitochondrial mass in DU145 or PC3 cells (Supplementary
Fig. S4e). The fact that loss of MFF does not affectmitochondrial dynam-
ics is consistent with a proposed role for other mitochondrial outer
membrane receptor(s) mediating Drp1 recruitment [32] and organelle
fission [33].
3.4. MFF associates with VDAC1 at the mitochondrial outer membrane
To test whether MFF had functions in cancer other than mitochon-
drial fission, we next carried out a proteomics screen for MFF-
associated molecules in PC3 cells (our unpublished observations). Onedent Myc accumulation at theMFF promoter in Burkitt lymphoma P493 cells at three time
NGP cell lines. (b) ChIP of Myc accumulation at the MFF promoter in PC3 cells transfected
. Mean± SD. **, p= .004; ns, not significant (by two-sided unpaired t-test). (c and d) PC3
CR (c) or Western blotting (d). Mean ± SD. **, p= .002 (by two-sided unpaired t-test).
irected shRNA were analysed for changes in Myc mRNA expression in the presence or
hep21 cells were analysed for MFF expression with or without Dox by quantitative PCR
Shep ER neuroblastoma cells stably transfected with a 4OHT-inducible N-Myc transgene
uantitative PCR. Mean ± SD. ***p b .0001 (by two-sided unpaired t-test).
ial fission factor is a novel Myc-dependent regulator of mitochondrial
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6 J.H. Seo et al. / EBioMedicine xxx (2019) xxxof the top hits in the screenwas VDAC1 (our unpublished observations).
Consistent this prediction, MFF1 (Fig. 3a) and MFF2 (Fig. 3b) co-
immunoprecipitated with VDAC1 in PC3 cells, in vivo. Other mitochon-
drial outermembrane proteins that bindVDAC1, including hexokinase-I
(HK-I) and -II (HK-II) were also present in the MFF-VDAC1 complex in
PC3 cells (Fig. 3a and b). In contrast, the MFF ligand, Drp1 did not co-
immunoprecipitate with the MFF-VDAC1 complex (Fig. 3b). Finally,
this interaction was selective as another MFF isoform, MFF5 did not as-
sociate with VDAC1 or HK-I, by co-immunoprecipitation in PC3 cells
(Fig. 3c).
Based on these data, we next asked if MFF regulated VDAC1 function
in cancer [17]. In these experiments, disruption of theMFF-VDAC1 com-
plex by MFF knockdown triggered increased permeability of the mito-
chondrial outer membrane, by quantification of mitochondrial calceinFig. 3.MFF regulation of mitochondrial outer membrane permeability. (a–c) PC3 cells were tra
(IP) with an antibody to Flag and analysed byWestern blotting. Sup, supernatant; Unb, unboun
labelledwith calcein in thepresence of CoCl2 and analysed byflow cytometry. Numbers indicate
siCtrl or siMFF were incubated with Fluoro3-AM and FLUO-5 N or, alternatively Rhod2-AM, an
associated Ca 2+ levels were determined by flow cytometry (e, representative experiment)
(top) or PC3 (bottom) cells were transfected with siCtrl or MFF-directed siRNA (siMFF) a
cytometry with or without suboptimal concentrations of the uncoupler, FCCP. Representative
in siRNA-transfected DU145 and PC3 cells. Mean ± SD.
Please cite this article as: J.H. Seo, E. Agarwal, Y.C. Chae, et al., Mitochondr
permeability in can..., EBioMedicine, https://doi.org/10.1016/j.ebiom.2019fluorescence and flow cytometry (Fig. 3d). This response was quantita-
tively comparable to the increase in mitochondrial outer membrane
permeability induced by H2O2 treatment (Fig. 3d) and was not further
increased in the combination of H2O2 plus MFF knockdown (Supple-
mentary Fig. S5a). Consistent with increased outer membrane perme-
ability, MFF silencing in PC3 was also associated with increased levels
ofmitochondrial-associated Ca2+ and concomitant decrease in cytosolic
Ca2+ (Fig. 3e and f). Conversely, ER-associated Ca2+ concentrations
were not significantly different in control or MFF-targeted cells
(Fig. 3e and f). In addition, MFF silencing in DU145 or PC3 cells was as-
sociatedwith loss ofmitochondrial innermembrane potential, in a reac-
tion further amplified by suboptimal concentrations of the uncoupler,
carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) (Fig. 3g
and h). Conversely, MFF silencing did not depolarize mitochondria innsfected with vector, Flag-MFF1 (a), Flag-MFF2 (b) or Flag-MFF5 (c), immunoprecipitated
d. (d) PC3 cells transfected with siCtrl or siMFF (top) or treated with H2O2 (bottom) were
fluorescence units per each condition. None, untreated. (e and f) PC3 cells transfectedwith
d changes in mitochondrial (Mito)-, endoplasmic reticulum (ER)- or cytosolic (Cytosol)-
and quantified (f). Numbers correspond to fluorescence units. Mean ± SD. (g) DU145
nd analysed for mitochondrial inner membrane potential by TMRE staining and flow
experiment (n= 3). (h) The conditions are as in (g) and TMRE staining was quantified
ial fission factor is a novel Myc-dependent regulator of mitochondrial
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Fig. S5b), which had basal levels of mitochondrial transmembrane po-
tential comparable to tumour cells (Fig. 3g and Supplementary Fig. S5b).
3.5. MFF control of tumour bioenergetics
Depolarization of themitochondrial inner membrane uncouples the
TCA cycle, and, accordingly, MFF-targeted cells exhibited extensive bio-
energetics defects. This included suppression of Oxygen Consumption
Rates (OCR), a marker of oxidative phosphorylation (Fig. 4a), with sig-
nificant decrease in both basal and maximal respiratory capacity
(Fig. 5b). Further, MFF knockdown in DU145 and PC3 cells was accom-
panied by loss of Extracellular Acidification Rates (ECAR) (Supplemen-
tary Fig. S5c) and decreased glycolysis as well as glycolytic capacity,
compared to control transfectants (Supplementary Fig. S5d).
Consistent with impaired bioenergetics, MFF silencing nearly
completely abolished ATP production in prostate cancer cells (Fig. 4c).
This was associated with oxidative stress and increased production of
mitochondrial-derived ROS after MFF knockdown (Fig. 4d). Because of
these bioenergetics defects, MFF-targeted DU145 and PC3 cells exhib-
ited hallmarks of nutrient deprivation, with increased phosphorylation
(Thr172) of the energy sensor, AMPK (Fig. 4e), differential phosphoryla-
tion of the autophagy activator, ULK1 with increased phosphorylation
on the AMPK (Ser555) and decreased phosphorylation on the mTOR
(Ser757) site (Fig. 4e), and induction of autophagy, with increasedFig. 4.MFF regulation of mitochondrial oxidative metabolism. (a) DU145 (top) or PC3 (bottom
(OCR) on a Seahorse XFe96 Bioenergetics Flux Analyzer. Mean ± SD (n= 3). (b) The conditio
and maximal (bottom) respiratory capacity. Mean ± SD (n = 3). ***, p = .0009 - b0.0001
production was quantified in siRNA-transfected cells. Mean ± SD. ***, p b .0001; **, p= .001
as in (a) were analysed for mitochondrial superoxide (mitoSox) production by fluorescence m
cells transfected with increasing concentrations of siMFF (10–20 nM) were analysed by Wes
siCtrl or siMFF and analysed by confocal fluorescence microscopy for analysis of cells with pu
were incubated with or without the autophagy inhibitor Bafilomycin A1 (BafA1) and analyse
AU, arbitrary units.
Please cite this article as: J.H. Seo, E. Agarwal, Y.C. Chae, et al., Mitochondr
permeability in can..., EBioMedicine, https://doi.org/10.1016/j.ebiom.2019punctate LC3 staining, by fluorescence microscopy (Fig. 4f, Supplemen-
tary Fig. S5e). Accordingly, loss of MFF resulted in the accumulation of
autophagy markers, p62 and LC3β, compared to control transfectants,
in a response further augmented by treatment with the autophagy in-
hibitor, Bafilomycin A1 (Fig. 4g).3.6. MFF regulates mitochondrial cell death
Consistent with a general collapse of mitochondrial integrity,
concentration-dependent depletion of MFF by siRNA (Fig. 5a) was asso-
ciated with mitochondrial-dependent killing of DU145 and PC3 cells
(Fig. 5b). This response had hallmarks of apoptosis, including mem-
brane blebbing and chromatin condensation (Fig. 5c), proteolytic pro-
cessing of PARP (Fig. 5d) and increased Annexin V labelling (Fig. 5e).
When combined with other stress stimuli, including nutrient depriva-
tion, oxidative stress (H2O2) or chemotherapeutic agents, etoposide or
doxorubicin, MFF knockdown further augmented PARP cleavage in
prostate cancer cells (Supplementary Fig. S6a). In addition tomitochon-
drial cell death, VDAC1 has been proposed as a regulator of Parkin-
dependent mitophagy [34]. Conversely, we found that knockdown of
MFF in PC3 cells did not significantly affect pH-sensitive fluorescence
emissions of a mitochondrial Keima-Red reporter (Fig. 5f), which quan-
tifies mitophagy (Supplementary Fig. S6b), compared to control
transfectants.) cells were transfected with siCtrl or siMFF and analysed for oxygen consumption rates
ns are as in (a) and siRNA-transfected DU145 or PC3 cells were quantified for basal (top)
(by two-sided unpaired t-test). (c) The conditions are as in (a) and the rate of ATP
(by two-sided unpaired t-test). (d) siRNA-transfected DU145 (top) or PC3 (bottom) cells
icroscopy. Mean ± SD. ***, p b .0001 (by two-sided unpaired t-test). (e) DU145 or PC3
tern blotting. p, phosphorylated. (f) PC3 cells expressing LC3-GFP were transfected with
nctate LC3-GFP staining. Scale bar, 20 μm. (g) PC3 cells transfected with siCtrl or siMFF
d by Western blotting. Bars, densitometric quantification of p62 and LC3β protein bands.
ial fission factor is a novel Myc-dependent regulator of mitochondrial
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Fig. 5.MFF inhibition ofmitochondrial cell death. (a and b)DU145 (top) or PC3 (bottom) cells transfectedwith siCtrl or increasing concentrations of siMFF (100–200nM)were analysed by
Western blotting (a) andmitochondrial-dependent cell viability was determined by anMTT assay (b).Mean± SD (n=3). ***, p b .0001 (by two-sided unpaired t-test). (c) PC3 cells were
transfectedwith siCtrl or siMFF and analysed for cellularmorphology by light contrastmicroscopy. Arrows, cells withmembrane blebbing and chromatin condensation. Scale bars, 50 μm.
(d) Two independent clones of DU145 or PC3 cells stably expressing shMFF (MFF #1 and MFF #2) or pLKO were analysed by Western blotting. Cl., cleaved. Bar graph, densitometric
quantification of total PARP (t-PARP) bands. RU, relative units. (e) DU145 (left) or PC3 (right) cells were transfected with siCtrl or siMFF and analysed for Annexin V and propidium
iodide (PI) staining by multiparametric flow cytometry. The percentage of cells in each quadrant is indicated. (f) PC3 cells stably expressing a mitochondrial Keima-Red reporter were
transfected with siCtrl or siMFF and analysed for pH-sensitive changes in fluorescence emission (PE-Texas Red) indicative of mitophagy. The percentage of cells in each quadrant is
indicated. Representative experiment. BV605, Brilliant Violet 605 (g and h). WT, VDAC1−/− or CypD−/−MEF were transfected with siCtrl or siMFF and analysed for cell viability by
Trypan blue exclusion and direct cell counting after 48 h (g) or an MTT assay (h). Mean ± SD. ***, p b .0001; **, p = .001; ns, not significant (by two-sided unpaired t-test). (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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lencing, we next used genetically-modified mouse embryonic fibro-
blasts (MEF) that express endogenous levels of MFF1 and MFF2
(Supplementary Fig. S6c). Consistentwith the data above,MFF silencing
induced cell death in wild type (WT) MEF, as determined by Trypan
blue exclusion and lightmicroscopy (Fig. 5g). In contrast, MEF knockout
for VDAC1 (Supplementary Fig. S6c)were entirely resistant to cell death
induced byMFF silencing (Fig. 5g). Similarly, MEFwith homozygous de-
letion of Cyclophilin D (CypD), an essential effector of regulated necro-
sis, were protected from cell death after MFF loss (Fig. 5g). We next
carried out similar studies by quantifying mitochondrial-associated
cell death by an MTT assay. Similar to the data above, MFF silencing
killed WT MEF, whereas VDAC1 knockout or CypD knockout MEF
were not affected (Fig. 5h).Please cite this article as: J.H. Seo, E. Agarwal, Y.C. Chae, et al., Mitochondr
permeability in can..., EBioMedicine, https://doi.org/10.1016/j.ebiom.20193.7. MFF is required for tumour growth
Based on these data, we next looked at the impact of MFF targeting
on tumorigenesis. siRNA silencing of MFF inhibited PC3 (Fig. 6a) or
DU145 (Supplementary Fig. S6d) cell proliferation, compared to control
transfectants. Stable knockdown of MFF by shRNA gave similar results,
suppressing DU145 or PC3 cell proliferation, compared to pLKO cultures
(Fig. 6b). This response was not limited to prostate cancer, as MFF si-
lencing inhibited glioblastoma LN229 or neuroblastoma SK-N-SH cell
proliferation (Supplementary Fig. S6d). Consistent with oxidative stress
in these settings, MFF knockdown caused extensive cell cycle defects in
tumour cells (Fig. 6c, Supplementary Fig. S6f), characterized by accumu-
lation of cells with G2/MDNA content (Fig. 6d). To confirm the specific-
ity of this response, we next reconstituted MFF-depleted PC3 cells withial fission factor is a novel Myc-dependent regulator of mitochondrial
.09.017
Fig. 6.MFF regulation of tumour cell proliferation. (a) PC3 cells were transfected with siCtrl or two independent MFF-directed siRNA (siMFF #A and siMFF #C) and analysed for cell
proliferation by direct cell counting during a 3-day interval. Each tracing corresponds to an individual experiment (n = 3). ***, p = .0002–0.0003 (by two-sided unpaired t-test).
(b) DU145 (left) or PC3 (right) cells stably transduced with pLKO or MFF-directed shRNA (shMFF) were analysed for cell proliferation by direct cell counting at the indicated time
intervals. Each tracing corresponds to an individual experiment (n = 3). ***, p b .0001 (by two-sided unpaired t-test). (c and d) PC3 cells transfected with siCtrl or siMFF were
analysed for DNA content by PI staining and flow cytometry (c, representative experiment; numbers correspond to the percentage of cells in each peak) and the percentage of cells in
the indicated cell cycle phase was quantified (d). Mean ± SD (n = 2). (e and f) PC3 cells transduced with pLKO or shMFF were reconstituted with MFF2 cDNA and analysed by
Western blotting (e) or cell proliferation by direct cell counting after 72 h (f). The position of endogenous or Flag-MFF2 is indicated. Mean ± SD (n = 8). ***, p b .0001; ns, not
significant (by two-sided unpaired t-test). (g and h) PC3 or DU145 cells stably transduced with two independent MFF-directed shRNA (clones #1 and #2) or pLKO were analysed for
colony formation after 14 d by crystal violet staining (g, representative experiment) and quantified (h). Mean ± SD (n = 4). ***, p ≤.0001–0.003 (by two-sided unpaired t-test).
(i) PC3 cells stably transduced with pLKO (top) or shMFF (bottom) were injected s.c. on the flanks of immunocompromised athymic nude mice and tumour growth was measured at
the indicated time intervals with a calliper. Each symbol corresponds to an individual tumour. Tumour measurements (mm3) at day 30 are as follows: pLKO, 292.3 ± 40.1 (n = 9);
MFF shRNA, 124.4 ± 35.4 (n = 9). **, p = .006 (by two-sided unpaired t-test). (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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expression of MFF2 restored PC3 cell proliferation to levels of pLKO
transfectants (Fig. 6f). When analysed for hallmark of tumorigenicity,
shRNA knockdown of MFF potently suppressed colony formation
(Fig. 6g and h), and inhibited s.c. xenograft tumour (PC3) growth in im-
munocompromisedmice (Fig. 6i). As control, pLKO transfectants exhib-
ited extensive colony formation (Fig. 6g and h) and gave rise to
exponentially growing tumours in mice (Fig. 6i).
4. Discussion
In this study, we have shown that a regulator of mitochondrial dy-
namics, MFF is a direct transcriptional target of oncogenic Myc, and be-
comes overexpressed in primary and metastatic cancer, compared to
normal tissues. Biochemically, MFF isoforms MFF1 or MFF2 associate
with VDAC1 at the mitochondrial outer membrane. Disruption of this
complex by MFF silencing increases the permeability of the mitochon-
drial outer membrane followed by general collapse of organellePlease cite this article as: J.H. Seo, E. Agarwal, Y.C. Chae, et al., Mitochondr
permeability in can..., EBioMedicine, https://doi.org/10.1016/j.ebiom.2019functions with Ca2+ unbalance, loss of inner membrane potential, ex-
tensive bioenergetics defects and oxidative stress. In turn, this activates
multiplemitochondrial cell death pathways resulting in preclinical inhi-
bition of tumour cell proliferation, suppression of colony formation and
reduced xenograft tumour growth in mice.
Although deregulated mitochondrial fission [19] is commonly ob-
served in cancer and implicated in advanced disease traits [20,24], a
contribution of MFF in these responses has not been previously inves-
tigated. The role of oncogenic Myc [35] in this pathway, which may
be responsible for the overexpression of MFF in primary and metasta-
tic tumours, in vivo, fits well with an expanding role of Myc in mito-
chondrial reprogramming in cancer. In addition to oxidative
phosphorylation gene expression [36] and modulation of multiple
bioenergetics pathways [37], Myc-directed transcription has been as-
sociated with mitochondrial dynamics, promoting changes in organ-
elle structure that favour therapy resistance [38] or heightened
subcellular mitochondrial trafficking to fuel tumour cell invasion and
metastasis [29].ial fission factor is a novel Myc-dependent regulator of mitochondrial
.09.017
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ous observations [22,23], we uncovered here a much broader function
ofMFF in preserving organelle integrity in cancer. Biochemically, this in-
volved a novel complex between MFF and VDAC1 at the mitochondrial
outer membrane. Structurally organized as a transmembrane β-barrel
with an N-terminal domain arranged as an α-helix [16], VDAC1 acts
as a voltage-gated channel controlling the exchange of small ions and
metabolites across the mitochondrial outer membrane, sustaining a
host of organelle functions [15]. The complex phenotype of MFF-
targeted cells, characterized by a general collapse of mitochondrial bio-
energetics, Ca2+ influx, oxidative stress potentially responsible for
downstreamcell cycle defects and induction ofmultiple cell death path-
ways is consistent with this view, and suggests that MFF is a novel reg-
ulator of VDAC1 functions in cancer. The loss of HK-I [39] and HK-II [40]
from an MFF-VDAC1 complex is expected to further exacerbate this re-
sponse, increasing cell death and preventing compensatory bioenerget-
ics via glycolysis.
How MFF regulates VDAC1 functions, especially with respect to cell
death induction, remains to be fully elucidated. We know that VDAC1
contributes to mitochondrial outer membrane permeability in concert
with Bcl2 family proteins [11], but the role of channel conductance in
this response has been debated [12]. Evidence from electrophysiologic
studies and reconstitution experiments in artificialmembranes suggests
that VDAC1 assembles in higher-order multimers that modulate chan-
nel conductance in an “open” or “closed” configuration [15]. It is possi-
ble that MFF binding to VDAC1 regulates this process in tumour cells,
shutting off channel conductance and opposing cell death without af-
fecting Parkin-dependent mitophagy [34]. Such pro-survival function
is consistent with a recent role of MFF in maintaining the cancer stem
cell compartment in prostate cancer [41], and may counter the propen-
sity to cell death associated with mitochondrial fission [25], facilitating
its exploitation for tumour growth [42,43] and metastasis [44,45].
Disruption of an MFF-VDAC1 complex by MFF silencing was associ-
ated withmorphologic and biochemical hallmarks of apoptosis [14], in-
cluding Annexin V reactivity, PARP cleavage and VDAC1 dependence.
However, MFF targeting induced features of other cell death pathways
as well. For instance, the phenotype of severe nutrient deprivation in-
duced by MFF silencing was associated with autophagy [46], which
has been implicated in crosstalk with other cell death mechanisms
[47], whereas homozygous deletion of the obligatory effector of regu-
lated necrosis [48], CypD [49] entirely prevented cell death induced by
MFF silencing. While the relative contribution of autophagy, apoptosis
and regulated necrosis to the inhibition of tumour growth after MFF si-
lencing remains to be delineated, the coexistence of multiple cell death
pathways is not uncommon as a consequence of acute mitochondrial
dysfunction [50] and reflects mechanistic overlap of cell death re-
sponses [51].
Consistent with a general collapse of mitochondrial integrity, MFF
targeting delivered preclinical anticancer activity, with inhibition of tu-
mour cell proliferation, suppression of colony formation and impaired
tumour growth in mice. The differential overexpression of MFF in can-
cer, coupled with the insensitivity of normal cells to mitochondrial de-
polarization after MFF loss suggests that an MFF-VDAC1 complex may
provide an actionable therapeutic target in cancer. Because only MFF1
and MFF2 bind VDAC1, in vivo, sequence(s) uniquely present in these
isoforms, specifically Val199-Arg271 inMFF1 and the corresponding re-
gion Val 148-Arg220 in MFF2, would be predicted to form the VDAC1
binding interface and regulate channel conductance [15]. As it is now
feasible to disrupt protein-protein interactions at the mitochondrial
outer membrane [8], isoform-specific MFF mimetics targeting these se-
quences may compete for VDAC1 binding, trigger global organelle col-
lapse and exert anticancer activity, in vivo. Compared to current
mitochondrial-directed therapies [14], targeting the MFF-VDAC1 com-
plex may offer broader indications in heterogeneous tumours and its
mechanism of action involving multiple cell death pathways may
evade drug resistance maintained by antiapoptotic Bcl2 proteins [10].Please cite this article as: J.H. Seo, E. Agarwal, Y.C. Chae, et al., Mitochondr
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